Using the pan-cancer analysis in the Tumor Immune Estimation Resource (TIMER) database (Figure 7A) and TCGA database (Figure 7B), we observed that DIAPH3 was highly expressed in cervical cancer and multiple tumors. Here, DIAPH3 is linked to cervical carcinoma.